Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003569 · ClinicalTrials.gov registry record
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
A clinical trial, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- 2
- Enrollment target
NCT00003569 is a clinical trial that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT00003569 has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of dimesna in treating patients with solid tumors who are receiving cisplatin and paclitaxel.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG dimesna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 1998-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003569
The ClinicalTrials.gov registry entry for NCT00003569 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00003569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003569 about?
NCT00003569 is a clinical study titled "Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of dim...
What is the current status of trial NCT00003569?
This trial is currently completed. The enrollment target is 2 participants. The study started on 1998-03.
What interventions are being tested in trial NCT00003569?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), dimesna (DRUG).
Who is sponsoring clinical trial NCT00003569?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.